SANION Saniona AB

Saniona publishes its Annual Report for 2020

Saniona publishes its Annual Report for 2020

PRESS RELEASE

April 29, 2021

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the English version of the Annual Report for 2020 is now available on the company’s website, .

For more information, please contact

Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email:   

This information was submitted for publication, through the agency of the contact persons set out above, at 17.55 CEST on April 29, 2021.

About Saniona

Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain. Saniona’s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated. Lead candidate SAN711 is entering Phase 1 for rare neuropathic disorders, with SAN903 for rare inflammatory and fibrotic disorders advancing through preclinical development. Led by an experienced scientific and operational team, Saniona has an established research organization in Copenhagen, Denmark and is building its corporate office in the Boston, Massachusetts area, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at .

 

Attachment



EN
29/04/2021

Underlying

SANIONSaniona AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Saniona AB

Free Trial
SANION SANIONA AB

Saniona AB: 1 director

A director at Saniona AB bought 12,361 shares at 4.160SEK and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

10/03/24 October 3, 2024 1 EN
 PRESS RELEASE
Free
SANION SANIONA AB

Saniona AB’s Nomination Committee for the Annual General Meeting 2023

Saniona AB’s Nomination Committee for the Annual General Meeting 2023 PRESS RELEASE November 25, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced the composition of the Nomination Committee for the Annual General Meeting 2023. Pursuant to the instruction and charter for the Nomination Committee adopted by the general meeting, the Nomination Committee shall comprise of three members, which shall be the Chairman of the Board of Directors and two members appointed by the two largest shareholders as of last September. On September 30, 2022, the two larg...

November 25, 2022 1 EN
 PRESS RELEASE
Free
SANION SANIONA AB

Saniona AB:s valberedning inför årsstämman 2023

Saniona AB:s valberedning inför årsstämman 2023 PRESSMEDDELANDE 25 november 2022 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling, tillkännager idag valberedningens sammansättning inför årsstämman 2023 Enligt instruktionen och arbetsordningen för valberedningen som antagits av bolagsstämman ska valberedningen bestå av tre ledamöter, vilka ska vara styrelsens ordförande samt två ledamöter utsedda av de två största aktieägarna per den sista september. Den 30 september 2022 var de två största ägarna som önskar utse en representant till valberedningen Jørgen Drejer ...

November 25, 2022 1 EN
 PRESS RELEASE
Free
SANION SANIONA AB

Saniona publishes its interim report for the third quarter of 2022

Saniona publishes its interim report for the third quarter of 2022   Three Months Ended September 30, 2022 (2021)Nine Months Ended September 30, 2022 (2021)Revenue was SEK 2.4 M (2.3 M)Revenue was SEK 12.0 M (7.6 M)Operating profit/loss was SEK 21.8 M (-88.2 M)Net profit/loss was SEK 17.5 M (-93.7 M)Operating profit/loss was SEK -203.1 M (-286.7 M)Net profit/loss was SEK -204.4 M (-281.8 M)Basic earnings/loss per share was SEK 0.28 (-1.50)Basic earnings/loss per share was SEK -3.28 (-4.52)Diluted earnings/loss per share were SEK 0.28 (-1.50)Diluted earnings/loss per share were SEK -3.28 (-...

November 17, 2022 1 EN
 PRESS RELEASE
Free
SANION SANIONA AB

Saniona publicerar sin delårsrapport för det tredje kvartalet 2022

Saniona publicerar sin delårsrapport för det tredje kvartalet 2022   Q3 2022 (Q3 2021)Jan–sep 2022 (jan–sep 2021)Intäkter uppgick till 2,4 MSEK (2,3 M)Intäkter uppgick till 12,0 MSEK (7,6 M)Rörelseresultat uppgick till 21,8 MSEK (-88,2 M)Periodens resultat uppgick till 17,5 MSEK (-93,7 M)Rörelseresultat uppgick till -203,1 MSEK (-286,7 M)Periodens resultat uppgick till -204,4 MSEK (-281,8 M)Resultat per aktie uppgick till 0,28 SEK (-1,50)Resultat per aktie uppgick till -3,28 SEK (-4,52)Resultat per aktie efter utspädning uppgick till 0,28 SEK (-1,50)Resultat per aktie efter utspädning uppg...

November 17, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch